Clinical Trial Detail

Clinical Trials

Clinical Trial Detail

ESP1/SARC025 Global Collaboration: A Phase I Study of a Combination of the PARP Inhibitor, Niraparib and Temozolomide in Patients With Previously Treated, Incurable Ewing Sarcoma

Complete title: ESP1/SARC025 Global Collaboration: A Phase I Study of a Combination of the PARP Inhibitor, Niraparib, and Temozolomide in Patients with Previously Treated, Incurable Ewing Sarcoma

Research Study Number SC-6015
 
Principal Investigator Doug Hawkins, MD
 
Phase I

Research Study Description

The purpose of this study is to define the dose-limiting toxicities and maximum tolerated dose of the poly ADP-ribose polymerase inhibitor niraparib and escalating doses of temozolomide in patients with pre-treated incurable Ewing sarcoma.

Eligibility Criteria (must meet the following to participate in this study)

** For Eligibility information, please click on the "Look up trial at NIH" link above. **

Other eligibility criteria may apply.

Research Study Number SC-6015
 
Contact Advanced Therapeutics Study Line
 
Telephone 206/987-2553
 
E-mail
 

Keywords: Pediatric Cancers, Miscellaneous; Sarcoma; Solid Tumors; Sarcoma, Ewing

Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Please remember:

  • Talk to your health care providers first before making decisions about your health care.
  • Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.

Subscribe to an RSS feed of all trials